# EDGAR Filing Document

**Accession Number:** 0001442891
**File Stem:** 0001580642-25-005147
**Filing Date:** 2025-8
**Character Count:** 13549
**Document Hash:** e206179c8f14da9380a3bad06ea08587
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001580642-25-005147.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001580642-25-005147

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VYNE Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001566044
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 453757789
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90268
- **FILM NUMBER:** 251220444

**BUSINESS ADDRESS:**
- **STREET 1:** 685 ROUTE 202/206 N., SUITE 301
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
- **BUSINESS PHONE:** 800-775-7936

**MAIL ADDRESS:**
- **STREET 1:** 685 ROUTE 202/206 N., SUITE 301
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Menlo Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20180201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Menlo Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20170728

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tigercat Pharma, Inc.
- **DATE OF NAME CHANGE:** 20130104
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EVENTIDE ASSET MANAGEMENT, LLC
- **CENTRAL INDEX KEY:** 0001442891

**ORGANIZATION NAME:**
- **EIN:** 262508416
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** ONE INTERNATIONAL PLACE
- **STREET 2:** SUITE 4210
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 877-771-3836

**MAIL ADDRESS:**
- **STREET 1:** ONE INTERNATIONAL PLACE
- **STREET 2:** SUITE 4210
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EVENTIDE ASSET MANAGMENT LLC
- **DATE OF NAME CHANGE:** 20080813

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** VYNE Therapeutics Inc.

**Title of Class of Securities:** Common Stock, par value $0.0001

**CUSIP Number:** 92941V308

**Date of Event Which Requires Filing of this Statement:** 06/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Eventide Asset Management, LLC | Names of Reporting Persons<br>Eventide Asset Management, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>1849597.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>1849597.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1849597.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1849597.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.99% | Percent of Class Represented by Amount in Row (9)<br>9.99% |
| 12. | Type of Reporting Person (See Instructions)<br>IA | Type of Reporting Person (See Instructions)<br>IA |

---

| 1. | Names of Reporting Persons<br>Finny Kuruvilla, M.D. Ph. D. | Names of Reporting Persons<br>Finny Kuruvilla, M.D. Ph. D. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1849597.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1849597.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1849597.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1849597.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.99% | Percent of Class Represented by Amount in Row (9)<br>9.99% |
| 12. | Type of Reporting Person (See Instructions)<br>HC, IN | Type of Reporting Person (See Instructions)<br>HC, IN |

---

| 1. | Names of Reporting Persons<br>Robin C. John | Names of Reporting Persons<br>Robin C. John |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1849597.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1849597.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1849597.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1849597.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.99% | Percent of Class Represented by Amount in Row (9)<br>9.99% |
| 12. | Type of Reporting Person (See Instructions)<br>HC, IN | Type of Reporting Person (See Instructions)<br>HC, IN |

---

**Item 1(a). Name of Issuer:**
VYNE Therapeutics Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
685 Route 202/206 N., Suite 301, Bridgewater, NJ 08807

**Item 2(a). Name of Person Filing:**
(i)    Eventide Asset Management, LLC ("Eventide")
(ii)   Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla")
(iii)  Robin C. John ("John")

**Item 2(b). Address of Principal Business Office:**
Eventide, Kuruvilla and John:
One International Place, Suite 4210
Boston, Massachusetts 02110

**Item 2(c). Citizenship:**
Eventide:  Delaware
Kuruvilla:  United States
John:  United States

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.0001

**Item 2(e). CUSIP Number:**
92941V308

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [x] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [x] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

(i)     Eventide: 1,849,597
(ii)    Kuruvilla: 1,849,597
(iii)   John:       1,849,597

**(b) Percent of class:**

(i)     Eventide:     9.99%
(ii)    Kuruvilla:     9.99%
(iii)   John:           9.99%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

(1)   Eventide:     1,849,597
(2)   Kuruvilla:     0
(3)   John:           0

**(ii) Shared power to vote or to direct the vote:**

(1)   Eventide: 0
(2)   Kuruvilla: 1,849,597
(3)   John: 1,849,597

**(iii) Sole power to dispose or to direct the disposition of:**

(1)   Eventide:     1,849,597
(2)   Kuruvilla:     0
(3)   John:           0

**(iv) Shared power to dispose or to direct the disposition of:**

(1)   Eventide: 0
(2)   Kuruvilla: 1,849,597
(3)   John: 1,849,597

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

This Schedule 13G amendment is being filed to disclose a change in the mix of security types owned. As of June 30, 2025, Eventide is the beneficial owner of common stock of the Issuer ("Common Stock") issuable upon the exercise of pre-funded warrants (the "Warrants") as the investment adviser to Eventide Healthcare Innovation Fund I LP, a private fund (the "Fund"); provided that the Warrants may not be exercised if such exercise would cause the holder to beneficially own in excess of 9.99% of the number of shares of the Issuer's Common Stock then outstanding.

Eventide Asset Management, LLC is the Managing Member of Eventide Healthcare Innovation Fund I GP LLC which is the general partner of the Fund. The Warrants would be exercisable for up to 5,287,413 shares of Common Stock, subject to the limitation on exercise. If not for such limitation on exercise, the Reporting Persons would beneficially own in excess of 9.99% of the Issuer's Common Stock. The percentages reported herein regarding the Reporting Persons' holdings are calculated based upon information in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended on March 31, 2025, as filed with the Securities and Exchange Commission on May 8, 2025, citing  16,664,892 outstanding shares of Common Stock of the Issuer as of May 1, 2025.

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Eventide Asset Management, LLC**

**Date:** 08/14/2025

**By:** /s/ Peter J. Luiso

**Name & Title:** Peter J. Luiso, General Counsel

**Finny Kuruvilla, M.D. Ph. D.**

**Date:** 08/14/2025

**By:** /s/ Finny Kuruvilla, M.D., Ph. D.

**Name & Title:** Finny Kuruvilla, M.D., Ph. D.

**Robin C. John**

**Date:** 08/14/2025

**By:** /s/ Robin C. John

**Name & Title:** Robin C. John